Financial reports
10-K
2023 FY
Annual report
13 Mar 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
10-K
2022 FY
Annual report
22 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
10-K
2021 FY
Annual report
22 Mar 22
10-Q
2021 Q3
Quarterly report
9 Nov 21
Current reports
8-K
Generated full-year net FUROSCIX® revenue of $13.6 million, at the upper end of the range provided in January
13 Mar 24
8-K
Gross-to-net (GTN) discount of approximately 18% from launch through the end of Q4
4 Jan 24
8-K
Results of Operations and Financial Condition
8 Nov 23
8-K
Entry into a Material Definitive Agreement
20 Sep 23
8-K
Results of Operations and Financial Condition
10 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 23
8-K
Other Events
7 Jun 23
8-K
Announced launch and commercial availability of FUROSCIX® on February 20th
10 May 23
8-K
Financial Results and Provides Business Update
22 Mar 23
8-K
Other Events
10 Mar 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
22 Mar 24
S-8
Registration of securities for employees
13 Mar 24
S-3
Shelf registration
13 Mar 24
S-8
Registration of securities for employees
22 Mar 23
S-8
Registration of securities for employees
22 Mar 23
424B5
Prospectus supplement for primary offering
23 Nov 22
FWP
Free writing prospectus
22 Nov 22
424B5
Prospectus supplement for primary offering
21 Nov 22
S-8
Registration of securities for employees
22 Mar 22
S-3
Shelf registration
23 Mar 21
Proxies
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
DEFA14A
Additional proxy soliciting materials
27 Apr 21
DEF 14A
Definitive proxy
27 Apr 21
DEFA14A
Additional proxy soliciting materials
27 Apr 20
DEF 14A
Definitive proxy
27 Apr 20
DEFA14A
Additional proxy soliciting materials
30 Apr 19
DEF 14A
Definitive proxy
30 Apr 19
Other
EFFECT
Notice of effectiveness
25 Mar 24
EFFECT
Notice of effectiveness
30 Apr 21
CORRESP
Correspondence with SEC
27 Apr 21
UPLOAD
Letter from SEC
25 Mar 21
SEC STAFF LETTER
SEC staff letter
24 Mar 21
SEC STAFF
SEC staff action: Order
23 Feb 21
EFFECT
Notice of effectiveness
11 Feb 19
UPLOAD
Letter from SEC
8 Feb 19
CORRESP
Correspondence with SEC
7 Feb 19
CT ORDER
Confidential treatment order
17 Nov 17
Ownership
SC 13G/A
5AM Ventures IV, L.P.
14 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G
Rubric Capital Management LP
12 Feb 24
SC 13G/A
HIRSCHMAN ORIN
7 Feb 24
SC 13G
BlackRock Inc.
2 Feb 24
SC 13G/A
Cowen Financial Products LLC
2 Feb 24
4
Rachael Nokes
22 Jan 24
4
John H Tucker
22 Jan 24
SC 13G/A
MILLENNIUM MANAGEMENT LLC
12 Jan 24
4
Rachael Nokes
3 Jan 24